AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone & Propranolol
Description: Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine & Propranolol
Description: Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin 25-50 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: mecamylamine 1.25-5 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate 5-20 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: melatonin 3 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: midodrine 2.5-10 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: modafinil 100-200 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: octreotide 12.5-50 mcg Subcutaneous x 1 dose
Study NCT00262470 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose tablet x 1 pill
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 10-80 mg PO x 1-2 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil & Propranolol
Description: Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: sertraline 25-50 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV Saline
Description: 1 liter IV over 2 hours
Study NCT00262470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drinking Water
Description: 16 fluid ounces
Study NCT00262470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathing Device
Description: Breathing through a dead space tube
Study NCT00262470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: memantine 5-20 mg PO x 1 dose
Study NCT00262470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Description: Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
Study NCT01317797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: namilumab (MT203)
Description: administered three times, subcutaneous in the abdomen
Study NCT02854358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypozalix spray (artificial saliva)
Description: Hypozalix spray (artificial saliva)
Study NCT03967990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cornmeal flour
Description: 48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study NCT01317797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered three times, subcutaneous in the abdomen
Study NCT00419601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanyl
Description: Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
Study NCT00419601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
Study NCT01470651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 50mg - 250mg pills, taken each morning, for 14 weeks
Study NCT01470651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Inactive pill, matched to look like active medication
Study NCT03830788 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation by brachytherapy
Description: Brachytherapy by Iodine 125 delivering 144 Gy to the prostate
Study NCT03830788 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation by SBRT
Description: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
Study NCT02571283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail
Description: Administered as a single dose injection.
Study NCT02571283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Administered 20 minutes+ before additional medications.
Study NCT02571283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Administered 20 minutes or more after Exparel is administered.
Study NCT02657759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CARDICHOL
Study NCT02657759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT03967990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: antibody
Study NCT03967990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study NCT02870504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneoscleral limbus group
Description: Laser spot locates on the corneoscleral limbus
Study NCT02870504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one spot group
Description: Laser spot locates on one spot away from the corneoscleral limbus
Study NCT02870504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two spots group
Description: Laser spot locates on two spots away from the corneoscleral limbus
Study NCT00840372 — intervention group
Intervention type: PROCEDURE
Intervention: Buttonhole cannulation with semi-blunt needles
Description: Use of semi-blunt needles, compared to blunt needles, at every dialysis session
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: antibody
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: chemotherapy
Study NCT00611117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Level
Description: High vs. low physical activity during a high fat diet consumption.
Study NCT02783118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self administered online CBT
Description: The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts
Study NCT03257293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Cystoscopy
Description: The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
Study NCT03257293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Cystoscopy
Description: Routine cystoscopy as done as part of routine clinical practice
Study NCT03122756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
Study NCT03122756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: corticosteroide
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: corticosteroide
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: corticosteroide
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCNU
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: chemotherapy
Study NCT00209222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: chemotherapy
Study NCT06617845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation Set A and B
Description: Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.
Study NCT06623539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemafibrate high dose
Description: Pemafibrate 0.1 mg tablets shall be administered orally twice daily, two tablets per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 2 tablets 1 or 0.4 mg for 1 tablet 1 can be substituted.
Study NCT06623539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemafibrate low dose
Description: Pemafibrate 0.1 mg tablets shall be administered orally twice daily, one tablet per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 1 tablets 1 can be substituted.
Study NCT06623539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 53.3 mg tablets shall be administered orally once daily, one tablet per dose, after breakfast. Thereafter, the dose may be carefully increased to two tablets per dose at the physician\&amp;#39;s discretion.
Study NCT01381835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 7 days
Study NCT02299258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard stents MTN-CG-s-20/100
Description: The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
Study NCT02299258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored stents MTN-WE-20/100-A
Description: cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
Study NCT00485056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45mgs daily
Study NCT00485056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: 45mgs daily
Study NCT04229680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Salt
Description: Consumption of pills containing table salt for 10 days.
Study NCT04229680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Recommended Salt
Description: Consumption of pills containing dextrose for 10 days.
Study NCT04213313 — intervention group
Intervention type: DRUG
Intervention: Treatment of bacterial keratitis
Description: 0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
Study NCT04213313 — intervention group
Intervention type: DRUG
Intervention: Treatment of fungal keratitis
Description: 1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
Study NCT04213313 — intervention group
Intervention type: DRUG
Intervention: Treatment of viral keratitis
Description: 0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
Study NCT04213313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: corneal scraping
Description: culture and sensitivity of corneal ulcerated infiltrating edge tissue
Study NCT04213313 — intervention group
Intervention type: OTHER
Intervention: Sequencing
Description: polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
Study NCT04639089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platlet rich plasma on sternal healing post median sternotomy
Description: Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery
Study NCT04639089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: platlet rich plasma on sternal healing post median sternotomy
Description: Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery
Study NCT04181424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Plus Monthly Food Vouchers
Description: Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
Study NCT04181424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes
Description: Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
Study NCT04181424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Only
Description: Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
Study NCT04181424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Plus Monthly Stock Boxes
Description: Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
Study NCT01738893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: Test product
Study NCT01738893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: Reference product
Study NCT02439177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 3)
Study NCT02439177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 5)
Study NCT02381002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight reduction program
Description: Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
Study NCT02314741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM Procedure
Description: The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually \~6cm long \& averages 8-10cm. After the myotomy is performed the scope is withdrawn \& inserted into the lumen to inspect the mucosa, ensure mucosal integrity \& confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, \& is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
Study NCT06012565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND567
Description: 2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
Study NCT06012565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
Study NCT03917810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study NCT03917810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study NCT03748238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Injury with Hysteroscopy
Description: All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
Study NCT01416701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (D3, cholecalciferol)
Description: Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
Study NCT01416701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (cellulose)
Description: Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
Study NCT00979602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: One intramuscular injection
Study NCT00979602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: One intramuscular injection
Study NCT03767634 — intervention group
Intervention type: OTHER
Intervention: Parenteral nutrition
Description: Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
Study NCT01782040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auriculotherapy group
Description: It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
Study NCT00936221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: oral capsules, 75mg twice daily